Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study.

Rahmi Aslan,Şeyhmuz Araz,Kasim Ertas,Kerem Taken,Mehmet Sevim,Recep Eryılmaz,Hamit Hakan Alp,Zubeyir Huyut

doi:10.31557/apjcp.2020.21.2.505

Rahmi Aslan, Şeyhmuz Araz + Show 6 more

Open Access

https://doi.org/10.31557/apjcp.2020.21.2.505

Copy DOI

Abstract

Aim:There is much evidence of an association between cancer and irisin that is an adipokine. This study researched on the relationship between prostate cancer (PCa) and irisin levels, and whether irisin can be used as a biomarker in the diagnosis of PCa. Materials and Methods:For the study groups, 50 primary PCa patients and 30 healthy male subjects were included in the PCa and healthy control groups, respectively. All volunteers in the healthy control group were screened for prostate cancer and other malignancies and chronic diseases. Volunteers who were determine to be completely healthy were included for healthy control group. In the serum samples of the subjects were measured free PSA, total PSA and irisin levels. Irisin levels were compared separately in terms of the Gleason scores and T stage. In addition to intergroup comparisons, the ROC curve for the irisin was plotted and power analysis was performed. Results:Free and total PSA levels in the PCa group were significantly higher compared to the healthy control group (p<0.05). In addition, irisin levels in the PCa group were significantly lower than in the healthy control group (p<0.05). There was no significant difference between irisin levels in the groups classified in terms of Gleason scores (p>0.05). When the cut-off value was taken as 8.1, the sensitivity and specificity of irisin for PCa were as 80.5% and 90%, respectively. Conclusion:The results of this study indicate that the levels of irisin in the PCa group are considerably reduced and irisin may be used as a biomarker as well as free and total PSA.

Highlights

Irisin is a myokine/adipokine that has been identified in recent years and is widely study worldwide
This study researched on the relationship between prostate cancer (PCa) and irisin levels, and whether irisin can be used as a biomarker in the diagnosis of PCa
The results of this study indicate that the levels of irisin in the PCa group are considerably reduced and irisin may be used as a biomarker as well as free and total PSA

Summary

Introduction

Irisin is a myokine/adipokine that has been identified in recent years and is widely study worldwide. Irisin is produced by proteolytic cleavage of protein 5 (FNDC5) that is included fibronektin tip III domain (Boström et al, 2012). It is synthesized in many tissues including skeletal muscle and fat cells, and participates in the regulation of lipid and glucose metabolism (Aydin, 2014). By increasing levels of uncoupling protein-1 (UCP1), Irisin converts white adipose tissue cells into brown adipose tissue cells and reduces obesity (Boström et al, 2012). Many studies in recent years clearly show that there is a connection between irisin and cancer. Irisin has been shown to regulate division and proliferation in prostate cancer cells. Irisin has been shown to regulate division and proliferation in prostate cancer cells. (Tekin et al, 2015)

Objectives

Methods

Results

Conclusion